docetaxel anhydrous has been researched along with Radiation Pneumonitis in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Cheng, L; Cui, X; Du, X; Sheng, L | 1 |
| Hiraki, T; Kanazawa, S; Katayama, N; Katsui, K; Kiura, K; Kuroda, M; Maeda, Y; Ogata, T; Toyooka, S; Watanabe, K | 1 |
| Cha, J; Kim, SK; Koom, WS; Lee, CG; Lee, IJ; Lee, JY; Suh, YG | 1 |
| Dang, J; Li, G; Yao, L; Zang, S; Zhang, S | 1 |
| Bai, Y; Chen, M; Hu, Y; Li, H; Li, J; Li, Q; Li, T; Lu, B; Lu, Y; Ma, Z; Ouyang, W; Su, S; Wang, X; Wang, Y | 1 |
| Barriger, RB; Fakiris, AJ; Hanna, N; Mantravadi, P; McGarry, RC; Yu, M | 1 |
| Ichikawa, A; Kato, S; Kazumoto, T; Kudo, S; Kurimoto, F; Saito, Y; Saitoh, J; Sakai, H; Shibuya, K; Yoshida, D | 1 |
| Swartman, B | 1 |
| Araki, T; Ishihara, H; Komiyama, T; Kuriyama, K; Nishikawa, K; Onishi, H; Tanaka, S; Yamaguchi, M | 1 |
| Senan, S | 1 |
| Atalar, B; Dinçbas, FO; Koca, S | 1 |
| Abad, A; Arellano, A; Boix, J; Cardenal, J; Casas, D; Fernández-Llamazares, J; Font, A; Manzano, JL; Margelí, M; Rosell, R | 1 |
4 trial(s) available for docetaxel anhydrous and Radiation Pneumonitis
| Article | Year |
|---|---|
O02.03 Value of adding erlotinib to thoracic radiation therapy with chemotherapy for stage III non-small cell lung cancer: a prospective phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Erlotinib Hydrochloride; Esophagitis; Genes, erbB-1; Humans; Lung Neoplasms; Paclitaxel; Prospective Studies; Quinazolines; Radiation Injuries; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Analysis; Taxoids | 2014 |
Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; China; Cisplatin; Confidence Intervals; Disease-Free Survival; Docetaxel; Esophagitis; Female; Humans; Karnofsky Performance Status; Leukopenia; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Pemetrexed; Prospective Studies; Radiation Pneumonitis; Radiotherapy; Survival Rate; Taxoids; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2015 |
Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Humans; Lung; Lung Neoplasms; Middle Aged; Radiation Pneumonitis; Radiotherapy Dosage; Retrospective Studies; Taxoids; Tumor Burden | 2010 |
Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Comorbidity; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagitis; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Radiation Pneumonitis; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
9 other study(ies) available for docetaxel anhydrous and Radiation Pneumonitis
| Article | Year |
|---|---|
Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Prognosis; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Risk Factors; ROC Curve; Survival Rate | 2019 |
Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Glucocorticoids; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Prednisolone; Radiation Pneumonitis; Retrospective Studies; Withholding Treatment | 2020 |
High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Radiation; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Stenosis; Female; Fluorouracil; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Platinum Compounds; Prognosis; Radiation Pneumonitis; Radiotherapy Dosage; Retrospective Studies; Risk Factors; Taxoids; Treatment Failure; Treatment Outcome | 2014 |
Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiation Pneumonitis; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Risk Factors; Taxoids; Vinblastine; Vinorelbine | 2014 |
Concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin for stage III unresectable, non-small-cell lung cancer: clinical application of a protocol used in a previous phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Consolidation Chemotherapy; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiation Pneumonitis; Survival Rate; Taxoids | 2012 |
[Radiochemotherapy in non-small-cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Combined Modality Therapy; Diagnosis, Differential; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Lymph Node Excision; Neoplasm Staging; Pneumonectomy; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Taxoids; Tomography, X-Ray Computed | 2011 |
Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Pneumonitis; Radiotherapy; Survival Rate; Taxoids | 2003 |
Reply to "Radiation pneumonitis and docetaxel".
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lung Neoplasms; Radiation Pneumonitis; Radiotherapy; Survival Rate; Taxoids | 2004 |
Two-dimensional radiotherapy and docetaxel in treatment of stage III non-small cell lung carcinoma: no good survival due to radiation pneumonitis.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Radiation Pneumonitis; Risk Factors; Taxoids; Time Factors | 2004 |